AKTS Company Profile and Key Details

Q: Who are the executives of AKTS?

Mr. Andrew WrightGen. Counsel & Corporation Sec.Mr. Jeffrey B. ShealyFounder, Pres, Chief Executive Officer & DirectorMr. Kenneth E. BollerChief Financial Officer & Corporation ControllerMr. Kamran CheemaChief Product OfficerMr. David M. AicheleExecutive Vice President of Bus. Devel.Ms. Mary WintersExecutive Vice President of Fab & Corporation OperationsMr. Thomas Andrew SepenzisVice President of Corporation Devel. & IR

NASDAQ : AKTS

Aktis Oncology

$22.07

-0.93-4.04%

At Close 4:00 PM

61.81

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Aktis Oncology, Inc. (AKTS) stock declined over -4.04%, trading at $22.07 on NASDAQ, down from the previous close of $23.00. The stock opened at $23.04, fluctuating between $21.34 and $23.14 in the recent session.

Stock Snapshot

Prev. Close

1.18B

Market Cap

21.34

Day Low

-1.19

P/E Ratio

-18.57

EPS (TTM)

-0.72

Cash Flow per Share

23.04

Open

53.4M

Number of Shares

23.14

Day High

97.52%

Free Float in %

0.74

Book Value

269.67K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 31, 2026	23.04	23.14	21.34	22.07	278.44K
Jul 30, 2026	22.24	23.21	21.80	23.00	331.09K
Jul 29, 2026	23.05	23.48	22.27	22.39	306.87K
Jul 28, 2026	24.22	24.26	22.54	22.97	300.32K
Jul 27, 2026	24.16	25.20	24.16	24.21	258.79K
Jul 24, 2026	24.06	24.58	23.40	23.89	193.64K
Jul 23, 2026	24.35	24.69	23.60	24.01	298.69K
Jul 22, 2026	24.59	25.03	24.15	24.81	208K
Jul 21, 2026	23.76	25.22	23.76	24.63	244.6K
Jul 20, 2026	25.18	25.32	23.52	23.96	261.93K
Jul 17, 2026	24.64	26.03	24.28	24.89	260.63K
Jul 16, 2026	26.21	26.62	24.80	25.02	314.23K
Jul 15, 2026	24.85	26.16	24.23	26.00	432.46K
Jul 14, 2026	25.91	26.88	25.13	25.18	754.11K
Jul 13, 2026	27.31	27.39	24.26	25.58	667.39K
Jul 10, 2026	27.95	28.65	26.52	27.88	487.2K
Jul 09, 2026	28.70	29.54	28.03	28.42	371.17K
Jul 08, 2026	27.00	29.01	26.53	28.69	711.74K
Jul 07, 2026	26.78	29.01	26.75	27.58	486.53K
Jul 06, 2026	31.75	32.38	25.84	26.56	886.11K

Contact Details

Boston, MA 02210

United States

https://www.aktisoncology.com 617 461 4023

About Company

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.

Stock Peers

ARGX

-18.76-2.15%

argenx SE$853.82 REGN

24.29+3.29%

Regeneron Pharmaceuticals, Inc.$762.63 UTHR

-8.11-1.54%

United Therapeutics Corporation$517.71 VRTX

-4.6-0.95%

Vertex Pharmaceuticals Incorporated$477.10 MDGL

-25.79-5.23%

Madrigal Pharmaceuticals, Inc.$467.32 KRYS

-25.73-7.01%

Krystal Biotech, Inc.$341.12 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

-6.07-1.88%

BeOne Medicines AG$316.01 PRAX

0.08+0.03%

Praxis Precision Medicines, Inc.$307.83 LGND

-8.75-2.95%

Ligand Pharmaceuticals Incorporated$287.54

Company Overview

Aktis Oncology, Inc. (NASDAQ:AKTS) closed at $22.07 USD, losing -$0.93 (-4.04%) from the previous close of $23.00. The stock is currently mid-range between its 52-week high and low $14.72 and $34.19. With a market capitalization of about $1.18 billion, Aktis Oncology, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.01). Key stats such as the average daily volume over the past year has been around 348.71 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Aktis Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Matthew Roden, the company employs approximately 79 people and listed since January 09, 2026. Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 2.45%, SMA50 -1.31%, SMA200 -1.31%). The stock’s 14-day RSI is 48.45 (neutral), while the ATR of 1.69 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -32.68% below its high and over 16.85% above its low. Average 10-day trading volume of 268.94 thousand shares is below the 3-month average of 346.16 thousand, indicating normal recent market interest.

Valuation Metrics

Aktis Oncology, Inc. trades at a P/E ratio of -36.09, slightly below the S&P 500 average, with a price-to-sales ratio of 230.67 and a price-to-book ratio of 2.4 suggesting the stock is closer to book value. The P/FCF stands at -25.84, also above market averages.

Dividend & Fair Value

Aktis Oncology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.50. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$0.38. The next quarter is forecast at -$21.59. Next year's EPS is expected at $42.78. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $30.00. The high target offers 81.24% upside. The low target suggests 35.93% downside. The mean target is $33.50. This offers 51.79% upside. Aktis Oncology, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 22.58%. The prior quarter beat by -54.98%. Over the last six quarters, Apple has recorded several small beats. These include 90.91% in September 18, 2024.

Shareholding & Insider Activity

Aktis Oncology, Inc. has 53.40 million shares outstanding. The public float is 28.15 million shares, elevated short interest at 23.64% of float. This equals 3.74 million shares. The short ratio is 5.92 days. Institutional investors hold 86.52% of the float. Insiders own 14.14%. Shealy Jeffrey B. holds 2.22 million shares, McMahon Jeffrey has 484.34 thousand shares and Geiss Arthur has 415.92 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Aktis Oncology generated $27.38M in revenue, or $0.31 per share. Gross margin was -2.52%, operating margin -401.66%, and net profit margin -613.31%. Returns are negative, with ROA at -240.82% and ROE at 294.16%.
On valuation metrics, Aktis Oncology trades at a P/E of -36.09, P/S of 230.67 and P/B of 2.40. The current ratio is 19.49 and quick ratio is 19.49. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -529.35 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -3.41.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2024, Aktis Oncology posted revenue of $27.38M, down slightly from $27.12M in the prior quarter. Gross profit was - $689.00K (margin -2.52%). Operating income was - $109.99M (margin -401.7%). Net income was- $167.95M (EPS - $1.89).
The company ended the quarter with $24.45M in cash and short-term investments, a total debt of $52.86M, and net debt of $28.42M. Total assets were $69.74M, with equity of - $57.09M. Financials further reflected weakness, with operating cash flow of - $40.35M, free cash flow of - $46.34M, and capital expenditures of - $5.99M.

Price Forecast & Outlook

Our AI price prediction model suggests that Aktis Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.8%, with price expected at $23.35 by August 13, 2026, within a range of $19.41 to $27.23 3-Month Outlook: Projected rise of 277.53%, reaching $83.32 by October 28, 2026, with a range of $83.11 to $83.58. 1-Year Outlook: Projected gain of 17.35%, with price at $25.90 by July 30, 2027, within a range of $23.27 to $27.57.

Key Takeaways

Aktis Oncology, Inc. (NASDAQ:AKTS) shares are down -16.21% year-to-date currently trading near 52-week highs band. Valuation shows Aktis Oncology, Inc. trading at a premium to the broader market with a P/E of -36.09. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $15.50, suggesting -29.77% downside. Our AI forecast model points to short-term strength (5.8% over two weeks), a medium-term rise (277.53% over three months), and a longer-term gain (17.35% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Aktis Oncology, Inc. (AKTS) stock price?

Aktis Oncology, Inc. (NASDAQ: AKTS) stock price is $22.07 in the last trading session. During the trading session, AKTS stock reached the peak price of $23.14 while $21.34 was the lowest point it dropped to. The percentage change in AKTS stock occurred in the recent session was -4.04% while the dollar amount for the price change in AKTS stock was - $0.93.

AKTS's industry and sector of operation?

The NASDAQ listed AKTS is part of Biotechnology industry that operates in the broader Healthcare sector. Aktis Oncology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AKTS?

Mr. Andrew Wright
Gen. Counsel & Corporation Sec.
Mr. Jeffrey B. Shealy
Founder, Pres, Chief Executive Officer & Director
Mr. Kenneth E. Boller
Chief Financial Officer & Corporation Controller
Mr. Kamran Cheema
Chief Product Officer
Mr. David M. Aichele
Executive Vice President of Bus. Devel.
Ms. Mary Winters
Executive Vice President of Fab & Corporation Operations
Mr. Thomas Andrew Sepenzis
Vice President of Corporation Devel. & IR

How AKTS did perform over past 52-week?

AKTS's closing price is 49.93% higher than its 52-week low of $14.72 where as its distance from 52-week high of $34.19 is -35.45%.

How many employees does AKTS have?

Number of AKTS employees currently stands at 79.

Link for AKTS official website?

Official Website of AKTS is: https://www.aktisoncology.com

How do I contact AKTS?

AKTS could be contacted at phone 617 461 4023 and can also be accessed through its website. AKTS operates from 17 Drydock Avenue, Boston, MA 02210, United States.

How many shares of AKTS are traded daily?

AKTS stock volume for the day was 269.67K shares. The average number of AKTS shares traded daily for last 3 months was 348.71K.

What is the market cap of AKTS currently?

The market value of AKTS currently stands at $1.18B with its latest stock price at $22.07 and 53.4M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	79
Beta	0.01
Sales or Revenue	$27.38M
5Y Sales Change%	6.386%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

AKTS Company Profile and Key Details

Aktis Oncology

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways